Soleno Therapeutics Inc. (SLNO) Financial Statements (2025 and earlier)

Company Profile

Business Address 100 MARINE PARKWAY, SUITE 400
REDWOOD CITY, CA 94065
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3845 - Electromedical and Electrotherapeutic Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments256,776,000266,123,000149,627,000169,681,00052,437,00019,368,000
Cash and cash equivalent48,413,00057,024,00042,847,000169,681,00052,437,00019,368,000
Short-term investments208,363,000209,099,000106,780,000   
Other undisclosed current assets1,423,0001,379,0001,596,0001,677,0001,222,0001,130,000
Total current assets:258,199,000267,502,000151,223,000171,358,00053,659,00020,498,000
Noncurrent Assets
Operating lease, right-of-use asset2,992,000268,000338,000407,000474,000541,000
Property, plant and equipment196,00019,00027,00012,00015,00019,000
Long-term investments and receivables27,945,00028,482,0008,821,000   
Long-term investments27,945,00028,482,0008,821,000   
Intangible assets, net (including goodwill)7,291,0007,777,0008,263,0008,749,0009,235,0009,721,000
Intangible assets, net (excluding goodwill)7,291,0007,777,0008,263,0008,749,0009,235,0009,721,000
Other noncurrent assets83,00083,000165,000165,000165,000165,000
Total noncurrent assets:38,507,00036,629,00017,614,0009,333,0009,889,00010,446,000
TOTAL ASSETS:296,706,000304,131,000168,837,000180,691,00063,548,00030,944,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9,651,0005,865,0009,248,0006,284,0004,714,0004,607,000
Accounts payable6,243,0003,716,0008,022,0003,149,0003,216,0003,442,000
Accrued liabilities3,408,0002,149,0001,226,0003,135,0001,498,0001,165,000
Other liabilities3,101,0001,126,0001,511,0001,555,000848,000513,000
Other undisclosed current liabilities2,210,0002,159,0002,705,0003,666,00023,431,0003,678,000
Total current liabilities:14,962,0009,150,00013,464,00011,505,00028,993,0008,798,000
Noncurrent Liabilities
Long-term debt and lease obligation      
Long-term debt, excluding current maturities      
Liabilities, other than long-term debt2,581,000 37,000130,000214,000273,000
Other liabilities      
Operating lease, liability2,581,000 37,000130,000214,000273,000
Other undisclosed noncurrent liabilities14,464,00014,224,00011,950,00011,549,00011,121,0009,447,000
Total noncurrent liabilities:17,045,00014,224,00011,987,00011,679,00011,335,0009,720,000
Total liabilities:32,007,00023,374,00025,451,00023,184,00040,328,00018,518,000
Equity
Equity, attributable to parent264,699,000280,757,000143,386,000157,507,00023,220,00012,426,000
Common stock41,00038,00033,00032,00015,00010,000
Additional paid in capital660,041,000600,534,000441,267,000433,885,000288,320,000266,669,000
Accumulated other comprehensive income (loss)895,000(153,000)(106,000) (1,000) 
Accumulated deficit(396,278,000)(319,662,000)(297,808,000)(276,410,000)(265,114,000)(254,253,000)
Total equity:264,699,000280,757,000143,386,000157,507,00023,220,00012,426,000
TOTAL LIABILITIES AND EQUITY:296,706,000304,131,000168,837,000180,691,00063,548,00030,944,000

Income Statement (P&L) (USD)

12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
Operating expenses(80,212,000)(24,868,000)(23,475,000)(13,910,000)(10,382,000)(8,623,000)
Operating loss:(80,212,000)(24,868,000)(23,475,000)(13,910,000)(10,382,000)(8,623,000)
Nonoperating income (expense)3,596,0003,014,0002,077,0002,614,000(479,000)148,000
Investment income, nonoperating 3,596,0003,014,0002,077,000   
Other nonoperating income    2,144,000174,000147,000
Other undisclosed loss from continuing operations before equity method investments, income taxes      
Loss from continuing operations before equity method investments, income taxes:(76,616,000)(21,854,000)(21,398,000)(11,296,000)(10,861,000)(8,475,000)
Other undisclosed income from continuing operations before income taxes      
Net loss available to common stockholders, diluted:(76,616,000)(21,854,000)(21,398,000)(11,296,000)(10,861,000)(8,475,000)

Comprehensive Income (USD)

12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
Net loss:(76,616,000)(21,854,000)(21,398,000)(11,296,000)(10,861,000)(8,475,000)
Comprehensive loss:(76,616,000)(21,854,000)(21,398,000)(11,296,000)(10,861,000)(8,475,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1,048,000(47,000)(106,000)1,000(1,000)(16,000)
Comprehensive loss, net of tax, attributable to parent:(75,568,000)(21,901,000)(21,504,000)(11,295,000)(10,862,000)(8,491,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: